Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

被引：0

作者：

Nazzareno Galiè

Sean Gaine

Richard Channick

J. Gerry Coghlan

Marius M. Hoeper

Irene M. Lang

Vallerie V. McLaughlin

Cheryl Lassen

Lewis J. Rubin

Shu-Fang Hsu Schmitz

Olivier Sitbon

Victor F. Tapson

Kelly M. Chin

机构：

[1] University of Bologna and IRCCS-S.Orsola University Hospital,Alma Mater Studiorum

[2] Mater Misericordiae University Hospital,David Geffen School of Medicine

[3] UCLA,undefined

[4] Royal Free Hospital,undefined

[5] Hannover Medical School and German Centre for Lung Research (DZL/BREATH),undefined

[6] Medical University of Vienna,undefined

[7] University of Michigan,undefined

[8] Actelion Pharmaceuticals Ltd,undefined

[9] University of California,undefined

[10] San Diego,undefined

[11] Hôpital Bicêtre,undefined

[12] Cedars-Sinai Medical Center,undefined

[13] University of Texas Southwestern Medical Center,undefined

[14] Université Paris-Sud,undefined

[15] INSERM Unité 999,undefined

来源：

Advances in Therapy | 2022年 / 39卷

关键词：

Selexipag; Pulmonary arterial hypertension; PAH; GRIPHON; Open-label extension; Safety; Tolerability; Survival; Combination therapy; Long-term outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：796 / 810

页数：14

共 50 条

[31] FUTURE-2: Results froman open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (vol 202, pg 52, 2016)
Berger, Rolf M. F.
Haworth, Sheila G.
Bonnet, Damien
Dulac, Yves
Fraisse, Alain
Galie, Nazzareno
Ivy, D. Dunbar
Jais, Xavier
Miera, Oliver
Rosenzweig, Erika B.
Efficace, Michela
Kusic-Pajic, Andjela
Beghetti, Maurice
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 1072 - 1073
[32] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
Ketter, T. A.
Sachs, G. S.
Lu, K.
Ruth, A.
Laszlovszky, I.
Nagy, K.
Starace, A.
Durgam, S.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S377 - S377
[33] Open-label assessment of the long-term tolerability, safety, and efficacy of sertindole in patients with schizophrenia
Hale, T.
Murray, R. M.
Azorin, J. M.
Maehlum, E.
SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 431 - 432
[34] Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder
Ketter, T. A.
Sachs, G.
Lu, K.
Laszlovszky, I.
Nagy, K.
Starace, A.
Durgam, S.
BIPOLAR DISORDERS, 2013, 15 : 134 - 134
[35] Open-label assessment of the long-term tolerability, safety, and efficacy of sertindole in patients with schizophrenia
Hale, A.
Murray, R. M.
Azorin, J. M.
Maehium, E.
EUROPEAN PSYCHIATRY, 2007, 22 : S113 - S113
[36] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Cohen, Stanley
Pablos, Jose L.
Zhang, Nan
Rizzo, Warren
Muller, Gerhard
Padmanaban, Devi
Kivitz, Alan
Matsumoto, Alan K.
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[37] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
Banerji, A.
Hao, J.
Yu, M.
Bernstein, J.
Johnston, D.
Riedl, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
[38] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
Stahl, Steven M.
Cucchiaro, Josephine
Simonelli, D.
Severs, J.
Loebel, A.
SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
[39] Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease
Bakchine, S.
Rainer, M.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S529 - S529
[40] ELAMIPRETIDE IN THE MMPOWER-2 OPEN-LABEL EXTENSION TRIAL (OLE): LONG-TERM SAFETY AND TOLERABILITY
Karaa, Amel
Haas, Richard
Goldstein, Amy
Vockley, Gerard
Cohen, Bruce
MUSCLE & NERVE, 2018, 58 : S34 - S34

← 1 2 3 4 5 →